Cargando…

Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity

Serologic studies are crucial for clarifying dynamics of the coronavirus disease pandemic. Past work on serologic studies (e.g., during influenza pandemics) has made relevant contributions, but specific conditions of the current situation require adaptation. Although detection of antibodies to measu...

Descripción completa

Detalles Bibliográficos
Autores principales: Clapham, Hannah, Hay, James, Routledge, Isobel, Takahashi, Saki, Choisy, Marc, Cummings, Derek, Grenfell, Bryan, Metcalf, C. Jessica E., Mina, Michael, Barraquer, Isabel Rodriguez, Salje, Henrik, Tam, Clarence C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454079/
https://www.ncbi.nlm.nih.gov/pubmed/32544053
http://dx.doi.org/10.3201/eid2609.201840
_version_ 1783575456411287552
author Clapham, Hannah
Hay, James
Routledge, Isobel
Takahashi, Saki
Choisy, Marc
Cummings, Derek
Grenfell, Bryan
Metcalf, C. Jessica E.
Mina, Michael
Barraquer, Isabel Rodriguez
Salje, Henrik
Tam, Clarence C.
author_facet Clapham, Hannah
Hay, James
Routledge, Isobel
Takahashi, Saki
Choisy, Marc
Cummings, Derek
Grenfell, Bryan
Metcalf, C. Jessica E.
Mina, Michael
Barraquer, Isabel Rodriguez
Salje, Henrik
Tam, Clarence C.
author_sort Clapham, Hannah
collection PubMed
description Serologic studies are crucial for clarifying dynamics of the coronavirus disease pandemic. Past work on serologic studies (e.g., during influenza pandemics) has made relevant contributions, but specific conditions of the current situation require adaptation. Although detection of antibodies to measure exposure, immunity, or both seems straightforward conceptually, numerous challenges exist in terms of sample collection, what the presence of antibodies actually means, and appropriate analysis and interpretation to account for test accuracy and sampling biases. Successful deployment of serologic studies depends on type and performance of serologic tests, population studied, use of adequate study designs, and appropriate analysis and interpretation of data. We highlight key questions that serologic studies can help answer at different times, review strengths and limitations of different assay types and study designs, and discuss methods for rapid sharing and analysis of serologic data to determine global transmission of severe acute respiratory syndrome coronavirus 2.
format Online
Article
Text
id pubmed-7454079
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-74540792020-09-03 Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity Clapham, Hannah Hay, James Routledge, Isobel Takahashi, Saki Choisy, Marc Cummings, Derek Grenfell, Bryan Metcalf, C. Jessica E. Mina, Michael Barraquer, Isabel Rodriguez Salje, Henrik Tam, Clarence C. Emerg Infect Dis Perspective Serologic studies are crucial for clarifying dynamics of the coronavirus disease pandemic. Past work on serologic studies (e.g., during influenza pandemics) has made relevant contributions, but specific conditions of the current situation require adaptation. Although detection of antibodies to measure exposure, immunity, or both seems straightforward conceptually, numerous challenges exist in terms of sample collection, what the presence of antibodies actually means, and appropriate analysis and interpretation to account for test accuracy and sampling biases. Successful deployment of serologic studies depends on type and performance of serologic tests, population studied, use of adequate study designs, and appropriate analysis and interpretation of data. We highlight key questions that serologic studies can help answer at different times, review strengths and limitations of different assay types and study designs, and discuss methods for rapid sharing and analysis of serologic data to determine global transmission of severe acute respiratory syndrome coronavirus 2. Centers for Disease Control and Prevention 2020-09 /pmc/articles/PMC7454079/ /pubmed/32544053 http://dx.doi.org/10.3201/eid2609.201840 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Perspective
Clapham, Hannah
Hay, James
Routledge, Isobel
Takahashi, Saki
Choisy, Marc
Cummings, Derek
Grenfell, Bryan
Metcalf, C. Jessica E.
Mina, Michael
Barraquer, Isabel Rodriguez
Salje, Henrik
Tam, Clarence C.
Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity
title Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity
title_full Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity
title_fullStr Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity
title_full_unstemmed Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity
title_short Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity
title_sort seroepidemiologic study designs for determining sars-cov-2 transmission and immunity
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454079/
https://www.ncbi.nlm.nih.gov/pubmed/32544053
http://dx.doi.org/10.3201/eid2609.201840
work_keys_str_mv AT claphamhannah seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity
AT hayjames seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity
AT routledgeisobel seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity
AT takahashisaki seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity
AT choisymarc seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity
AT cummingsderek seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity
AT grenfellbryan seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity
AT metcalfcjessicae seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity
AT minamichael seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity
AT barraquerisabelrodriguez seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity
AT saljehenrik seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity
AT tamclarencec seroepidemiologicstudydesignsfordeterminingsarscov2transmissionandimmunity